Uniqmed Pharma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 89,684 | 1,077,229 | 1,911,494 | 1,452,620 | 928,671 | 121,048 | 11,655 | 38,206 |
| Profit before tax | 11,411 | 55,272 | 118,996 | 129,916 | 72,026 | -48,620 | - | - |
| Net profit | 10,840 | 47,284 | 101,131 | 110,428 | 61,222 | -48,620 | -31,336 | -88,220 |
| Equity | 11,185 | 49,509 | 150,640 | 261,068 | 322,290 | 273,670 | 242,334 | 154,114 |
| Liabilities | 44,454 | 331,087 | 337,719 | 357,014 | 369,598 | 244,322 | 328,806 | 320,423 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 | 0 | 341,992 | 369,787 |
| Current assets | 55,639 | 211,950 | 488,349 | 618,082 | 691,888 | 517,992 | 229,148 | 104,316 |
| Total assets | 55,639 | 211,950 | 488,349 | 618,082 | 691,888 | 517,992 | 571,140 | 474,103 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 16,170 | 4,451 | 1,018 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +1533.6% | +1101.1% | +77.4% | -24.0% | -36.1% | -87.0% | -90.4% | +227.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 19.5% | 22.3% | 20.7% | 17.9% | 8.8% | -9.4% | -5.5% | -18.6% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 96.9% | 95.5% | 67.1% | 42.3% | 19.0% | -17.8% | -12.9% | -57.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 12.1% | 4.4% | 5.3% | 7.6% | 6.6% | -40.2% | -268.9% | -230.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 12.7% | 5.1% | 6.2% | 8.9% | 7.8% | -40.2% | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 4.0 | 6.7 | 2.2 | 1.4 | 1.1 | 0.9 | 1.4 | 2.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 44,842 | 538,615 | 955,747 | 726,310 | 530,669 | 63,154 | 5,828 | 19,103 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Uniqmed Pharma - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-07-23 | 2026-07-26 | 1.27 |
| 2026-07-19 | 2026-07-22 | 164.77 |
| 2026-07-16 | 2026-07-17 | 164.77 |
| 2026-06-16 | 2026-06-28 | 164.77 |
| 2026-05-17 | 2026-05-24 | 166.31 |
| 2026-05-03 | 2026-05-14 | 1.54 |
| 2026-04-24 | 2026-04-29 | 1.54 |
| 2026-03-27 | 2026-03-27 | 185.57 |
| 2026-03-17 | 2026-03-22 | 185.57 |
| 2026-03-15 | 2026-03-16 | 20.80 |
| 2026-02-18 | 2026-03-11 | 20.80 |
| 2026-01-23 | 2026-01-25 | 1.10 |
| 2026-01-22 | 2026-01-22 | 430.84 |
| 2026-01-16 | 2026-01-21 | 429.74 |
| 2025-12-16 | 2025-12-21 | 0.06 |
| 2025-09-16 | 2025-09-16 | 76.06 |
| 2025-05-16 | 2025-05-27 | 74.63 |
| 2023-08-17 | 2023-08-20 | 147.95 |
| 2023-05-16 | 2023-05-31 | 147.23 |
| 2022-09-16 | 2022-09-18 | 138.18 |
Uniqmed Pharma - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Uniqmed Pharma, UAB (code 304499589) is a Private Limited Liability Company engaged in wholesale of pharmaceutical and medical goods. In 2025, the company generated €38.2K in revenue and recorded a net loss of €88.2K, showing that profitability remained under pressure despite a rebound in sales from the previous year. Revenue rose sharply year on year in 2025, but it remained well below the 2023 level of €121.0K, indicating a volatile three-year trajectory. Net losses narrowed from €48.6K in 2023 to €31.3K in 2024, then widened significantly in 2025. The balance sheet at the end of 2025 showed total assets of €474.1K, equity of €154.1K and liabilities of €320.4K. Long-term assets amounted to €369.8K, while short-term assets were €104.3K. The company’s financial structure reflects moderate leverage, with debt exceeding equity, and asset turnover remained low. In 2025, revenue per employee was €19.1K and loss per employee was €44.1K, confirming limited operating efficiency during the latest financial year.